Literature DB >> 27187879

[Ocular Manifestations in Sarcoidosis].

K Walscheid1, C Tappeiner2, A Heiligenhaus1.   

Abstract

Sarcoidosis is an inflammatory multi-organ disease of unknown pathogenesis, characterised by non-necrotising granulomata. Sarcoidosis predominantly manifests in the lung, but any other organ may be affected. Ocular involvement is present in about 25 to 50 % of patients. The most common ocular manifestation is uveitis, especially of the anterior eye segment. If ocular sarcoidosis is suspected, interdisciplinary assessment of the patient is mandatory, including laboratory tests, chest X-ray, assessment by a specialist in internal medicine and, ideally, histological evidence of granuloma formation in a tissue specimen. Other (infectious) causes of granulomatous inflammation need to be excluded, especially tuberculosis or syphilis. For the ophthalmological assessment, detection of granulomatous lesions is of particular importance, especially by visualising chorioretinal granuloma by fluorescein and indocyanin green angiography. Cystoid macular oedema and glaucoma are the most frequent complications limiting visual acuity. Corticosteroids, which can be administered either locally or systemically, are the mainstay of therapy. Depending on the clinical course and the development of ocular complications, systemic steroid-sparing immunosuppressive medication may be indicated. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27187879     DOI: 10.1055/s-0042-104063

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

Review 1.  [Ocular sarcoidosis : Diagnosis and therapy].

Authors:  E Gundlach; B Temmesfeld-Wollbrück; U Pleyer
Journal:  Ophthalmologe       Date:  2017-09       Impact factor: 1.059

Review 2.  [Association of the different forms of uveitis with inflammatory rheumatic diseases and their treatment].

Authors:  Nicole Stübiger; Sanaz Farrokhi; Yannik Gkanatsas; Christoph Deuter; Ina Kötter
Journal:  Z Rheumatol       Date:  2022-08-30       Impact factor: 1.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.